Schechter M, Moulton L H, Harrison L H
Department of Preventive Medicine, Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Brazil.
J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Aug 1;15(4):308-11. doi: 10.1097/00042560-199708010-00010.
Reports indicate that there is a dissociation between markers of HIV disease progression and clinical stage among subjects coinfected with human T-cell lymphotropic virus type I (HTLV-I) and HIV. HTLV-I coinfection does not appear to affect HIV viral load, currently considered to be the best marker of HIV disease progression. We measured HIV RNA levels in stored serum samples from 23 subjects with coinfection and 92 subjects with HIV single infection and examined the correlation with the CD4+ lymphocyte count. Subjects were recruited from an ongoing HIV cohort study in Rio de Janeiro, Brazil. In both groups, CD4+ lymphocyte counts declined with increasing levels of HIV RNA. In a linear regression analysis adjusting for HIV RNA serum level, coinfected individuals had an estimated 78% higher CD4+ lymphocyte count than those with single infection. Simultaneous adjustment for beta2-microglobulin level increased the difference, with coinfected individuals having 146% (p = 0.005, 95% CI: 32% to 359%) higher CD4+ counts. These data suggest that the higher CD4+ lymphocyte counts associated with coinfection do not provide immunologic benefit and may reflect HTLV-I-associated nonspecific lymphocyte proliferation. The results of this and other studies suggest that the CD4+ count cutoff values used in making clinical decisions in HIV infection may not be appropriate in coinfection. As with HIV single infection, HIV virus load may be the optimal surrogate marker for subjects with coinfection.
报告表明,在同时感染I型人类嗜T细胞病毒(HTLV-I)和HIV的受试者中,HIV疾病进展标志物与临床分期之间存在分离现象。HTLV-I合并感染似乎不会影响HIV病毒载量,而HIV病毒载量目前被认为是HIV疾病进展的最佳标志物。我们检测了23名合并感染受试者和92名单纯感染HIV受试者储存血清样本中的HIV RNA水平,并研究了其与CD4+淋巴细胞计数的相关性。受试者来自巴西里约热内卢一项正在进行的HIV队列研究。在两组中,CD4+淋巴细胞计数均随着HIV RNA水平的升高而下降。在一项针对HIV RNA血清水平进行校正的线性回归分析中,合并感染个体的CD4+淋巴细胞计数估计比单纯感染个体高78%。同时校正β2-微球蛋白水平后,差异增大,合并感染个体的CD4+计数高出146%(p = 0.005,95% CI:32%至359%)。这些数据表明,合并感染相关的较高CD4+淋巴细胞计数并未带来免疫益处,可能反映了HTLV-I相关的非特异性淋巴细胞增殖。本研究及其他研究结果表明,用于HIV感染临床决策的CD4+计数临界值在合并感染时可能并不适用。与单纯HIV感染一样,HIV病毒载量可能是合并感染受试者的最佳替代标志物。